Hepatican Ltd Recognised for Outstanding Presentation at BioSeed 2026

Hepatican Ltd was recognised at BioSeed 2026, one of the UK's leading life sciences investment events, with CEO Professor Clare Selden winning Best Presentation in her session.

Hosted by OBN, BioSeed brings together innovative biotech companies, investors and industry leaders to showcase emerging technologies with strong scientific and commercial potential. Hepatican's presentation highlighted the company's pioneering combined ATMP and medical device platform for the treatment of liver failure, addressing a major unmet clinical need where treatment options remain limited.

Professor Selden was named Best Presenter alongside fellow session winners from AdCab, XapHe and Big Picture Bio, reflecting the high calibre of companies participating in this year's event. The award represents further recognition of Hepatican's progress in translating decades of academic research into a potentially transformative therapy for patients with liver failure.

The recognition follows Hepatican's recent appearances at leading industry conferences and underscores growing interest in the company's innovative approach to developing next-generation liver support therapies.